Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: Results of a prospective, open-label, multicenter study

Investigative Radiology

Volumn 50, Issue 6, 2015, Pages 416-422

  Lauenstein, Thomas ^a   Ramirez Garrido, Francisco ^b   Kim, Young Hoon ^c   Rha, Sung Eun ^d   Ricke, Jens ^e   Phongkitkarun, Sith ^f   Boettcher, Joachim ^g   Gupta, Rajan T ^h   Korpraphong, Pornpim ⁱ   Tanomkiat, Wiwatana ^j   Furtner, Julia ^k   Liu, Peter S ^l   Henry, Maren ^m   Endrikat, Jan ^m,n  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c Seoul National University Bundang Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^f MAHIDOL UNIVERSITY   (Thailand)

^g SRH Wald Klinikum Gera   (Germany)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^m BAYER PHARMA AG   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

gadoxetate disodium; liver imaging; NSF; renal impairment

Indexed keywords

GADOXETIC ACID; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEPATOGRAPHY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; TARGET VARIABLE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; KIDNEY DISEASE; LIVER; MIDDLE AGED; PATHOLOGY; RISK; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; KIDNEY DISEASES; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84929323884     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000145     Document Type: Article

References (29)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. Grobner T. Gadolinium -a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
3. Goveia M, Chan BP, Patel PR. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;57:725-727.
4. Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65: 1095-1106, 1106e1-1106e7.
5. Pietsch H, Jost G, Frenzel T, et al. Efficacy and safety of lanthanoids as x-ray contrast agents. Eur J Radiol. 2011;80:349-356.
6. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
7. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582.
8. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
9. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459-466.
10. Bottcher J, Hansch A, Pfeil A, et al. Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. Eur J Radiol. 2013;82:1860-1869.
11. Zech CJ, Korpraphong P, Huppertz A, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg. 2014;101:613-621.
12. Ringe KI, Husarik DB, Sirlin CB, et al. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol. 2010;195:13-28.
13. Zizka J, Klzo L, Ferda J, et al. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol. 2007;62:186-191.
14. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT -a multicenter trial. J Comput Assist Tomogr. 2006;30:345-354.
15. Gschwend S, EbertW, Schultze-MosgauM, et al. Pharmacokinetics and imaging properties ofGd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566.
16. http://radiology.bayer.com/products/mri/contrast-agents/nsf-safety-update.
17. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2008/022090s000ltr.pdf.
18. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
19. FDA letter 06/02/2011. Release from postmarketing requirement. NDA 22-090. Reference ID:2954948 np.
20. Amet S, Launay-Vacher V, Clement O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogenique Systemique study. Invest Radiol. 2014;49:109-115.
21. Smorodinsky E, AnsdellDS, FosterZW, et al. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging. 2014. [Epub ahead of print].
22. Hanna RF, Finkelstone LA, Chow DS, et al. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol. 2014;2014:1-6.
23. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002;288:1882-1888.
24. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
25. Glockner JF. Hepatobiliary MRI: current concepts and controversies. J Magn Reson Imaging. 2007;25:681-695.
26. Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR ContrastMedium Safety Committee guidelines. Eur Radiol. 2013;23:307-318.
27. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm.
28. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/07/WC500094268.pdf.
29. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm 108919.htm.